TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2922487

Group type: EXPERIMENTAL
Intervention: Different types of information interventions to promote BSE practice
Number of subjects: 204

Group type: EXPERIMENTAL
Intervention: Sensory information about the breast
Number of subjects: 204
Study: 5015048

Group type: EXPERIMENTAL
Intervention: Prednisolone (20 mg daily for one day before and two days after irradiation)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: Mustine (intravenously)
Number of subjects: 88

Group type: COMPARATOR
Intervention: No preliminary treatment (Control group)
Number of subjects: 88
Study: 732468

Group type: EXPERIMENTAL
Intervention: Whole-gut irrigation (wgi)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Elemental diet
Number of subjects: 32

Group type: EXPERIMENTAL
Intervention: Whole-gut irrigation with antibiotics (neomycin-bacitracin-clindamycin)
Number of subjects: 32
Study: 30824584

Group type: EXPERIMENTAL
Intervention: cobimetinib combined with vemurafenib
Number of subjects: 0

Group type: COMPARATOR
Intervention: vemurafenib alone
Number of subjects: 0
Study: 28093533

Group type: EXPERIMENTAL
Intervention: Deworming intervention with 400 mg of albendazole and educational training about STH infection, treatment, and prevention, conducted twice (May 2013 and November 2013)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not explicitly mentioned)
Number of subjects: 0
Study: 25774698

Group type: EXPERIMENTAL
Intervention: Spouse-assisted lifestyle change intervention (nine monthly goal setting telephone calls to participants and support planning calls to spouses over 11 months)
Number of subjects: 255

Group type: EXPERIMENTAL
Intervention: Spouse-assisted lifestyle change intervention
Number of subjects: 255

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 255
Study: 22640934

Group type: EXPERIMENTAL
Intervention: Manu® soft hand brace
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 10
Study: 22097198

Group type: EXPERIMENTAL
Intervention: Cardioplegic solution with Salvia miltiorrhizae (SM)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Cardioplegic solution without Salvia miltiorrhizae (Control)
Number of subjects: 30
Study: 19214920

Group type: COMPARATOR
Intervention: Conventional therapy (CT) with human premixed insulin b.d. (n=20)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Intensified therapy (ICT) with Lispro at meals and NPH at bedtime (n=24)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Supplementary therapy (SIT) with human regular insulin at meals (n=17)
Number of subjects: 61
Study: 17264089

Group type: EXPERIMENTAL
Intervention: OSRA-A
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: OSRA-D
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: DAS28
Number of subjects: 466

Group type: EXPERIMENTAL
Intervention: OMERACT core set
Number of subjects: 466
Study: 15105863

Group type: EXPERIMENTAL
Intervention: New blackcurrant/calcium/gum drink (test product)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Original blackcurrant/calcium drink
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional blackcurrant drink (positive control)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Water (negative control)
Number of subjects: 16
Study: 12216339

Group type: EXPERIMENTAL
Intervention: Seretide (salmeterol + fluticasone)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Symbicort (formoterol + budesonide)
Number of subjects: 0
Study: 9817170

Group type: EXPERIMENTAL
Intervention: 4-1BB receptor
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: LTbeta-R
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Fas
Number of subjects: 0
Study: 7654642

Group type: EXPERIMENTAL
Intervention: Modified biophysical profile (computerised cardiotocography, amniotic fluid index, assessment of fetal breathing, tone and gross body movements)
Number of subjects: 145

Group type: COMPARATOR
Intervention: Standard cardiotocography and maximum pool depth
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Modified biophysical profile
Number of subjects: 145

Group type: EXPERIMENTAL
Intervention: Amniotic fluid index
Number of subjects: 145

Group type: COMPARATOR
Intervention: Maximum pool depth
Number of subjects: 145
Study: 2780057

Group type: EXPERIMENTAL
Intervention: Ketoprofen (100 mg in 5 ml saline)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Saline (5 ml)
Number of subjects: 18
Study: 1107090

Group type: EXPERIMENTAL
Intervention: 1% hydrocortisone in a stabilized 10% urea cream
Number of subjects: 49

Group type: COMPARATOR
Intervention: 0.1% betamethasone 17-valerate cream
Number of subjects: 49
Study: 31831384

Group type: EXPERIMENTAL
Intervention: Foods and beverages consumed at ECE centers
Number of subjects: 840

Group type: COMPARATOR
Intervention: Foods and beverages consumed elsewhere
Number of subjects: 840

Group type: EXPERIMENTAL
Intervention: Foods and beverages consumed on weekdays
Number of subjects: 840

Group type: COMPARATOR
Intervention: Foods and beverages consumed on weekends
Number of subjects: 840
Study: 31689320

Group type: EXPERIMENTAL
Intervention: Adhere4U mobile medication manager application
Number of subjects: 138

Group type: COMPARATOR
Intervention: Conventional care (control group)
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Self-reported adherence using BAASIS
Number of subjects: 138

Group type: EXPERIMENTAL
Intervention: Self-reported adherence using VAS
Number of subjects: 138
Study: 28362208

Group type: EXPERIMENTAL
Intervention: Ad5-EBOV high-dose group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Ad5-EBOV other dose groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Males
Number of subjects: 0

Group type: COMPARATOR
Intervention: Females
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing age groups
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing body mass index (BMI)
Number of subjects: 0
Study: 26573447

Group type: EXPERIMENTAL
Intervention: Topical chamomile oil, applied twice daily for 4 weeks
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo, applied twice daily for 4 weeks
Number of subjects: 26
Study: 22958202

Group type: EXPERIMENTAL
Intervention: AZD6370 10-650 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: AZD6370 50 and 80 mg
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: AZD6370 10-20 mg with food
Number of subjects: 0

Group type: COMPARATOR
Intervention: Short-acting insulin 4 U
Number of subjects: 0
Study: 22064369

Group type: EXPERIMENTAL
Intervention: MgSO(4) supplementation
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control
Number of subjects: 60
Study: 19896019

Group type: EXPERIMENTAL
Intervention: Partner-led recruitment approach
Number of subjects: 555

Group type: COMPARATOR
Intervention: Other recruitment strategies (clinicians, public events, local organizations, special events)
Number of subjects: 555
Study: 16827763

Group type: EXPERIMENTAL
Intervention: Levonorgestrel intrauterine system (LNG-IUS)
Number of subjects: 79

Group type: COMPARATOR
Intervention: Thermal balloon ablation
Number of subjects: 79
Study: 14735861

Group type: EXPERIMENTAL
Intervention: Intrarectal lidocaine, 20 mg (group 1)
Number of subjects: 140

Group type: COMPARATOR
Intervention: Placebo (group 2)
Number of subjects: 140
Study: 11274244

Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Losartan
Number of subjects: 17
Study: 9877141

Group type: EXPERIMENTAL
Intervention: V1 skate (V1)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: V2‐alternate (V2A)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: V2 skate (V2)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: V1, V2, V2A
Number of subjects: 10
Study: 8033498

Group type: EXPERIMENTAL
Intervention: Orlistat (30 to 1200 mg, three times a day for 9 to 10 days)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo (matching placebo, three times a day for 9 to 10 days)
Number of subjects: 171
Study: 2644922

Group type: EXPERIMENTAL
Intervention: Intraoperative radiation therapy (IORT)
Number of subjects: 119

Group type: COMPARATOR
Intervention: Conventional therapy
Number of subjects: 119
Study: 980651

Group type: EXPERIMENTAL
Intervention: Recall after 1 week
Number of subjects: 76

Group type: EXPERIMENTAL
Intervention: Recall after 6 weeks
Number of subjects: 76

Group type: COMPARATOR
Intervention: Retest after 1 week
Number of subjects: 76

Group type: COMPARATOR
Intervention: Retest after 6 weeks
Number of subjects: 76
Study: 30353208

Group type: EXPERIMENTAL
Intervention: Group A (hip fixed at 50° and knee flexed at 90° for 6 hours post-operatively)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Group B (hip elevated at 30° and knee flexed at 45° for 6 hours post-operatively)
Number of subjects: 135

Group type: COMPARATOR
Intervention: Group C (affected knee fully extended after surgery)
Number of subjects: 135
Study: 30179110

Group type: EXPERIMENTAL
Intervention: Paclitaxel (12 weekly doses) followed by 12 weeks of treatment with four cycles of anthracycline
Number of subjects: 242

Group type: EXPERIMENTAL
Intervention: Model combining tumor subtype and midtreatment ΔADC
Number of subjects: 242
Study: 27864165

Group type: EXPERIMENTAL
Intervention: Text to Move (TTM) intervention group
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 126
Study: 24815121

Group type: EXPERIMENTAL
Intervention: Comprehensive education program based on the Theory of Planned Behavior (TPB)
Number of subjects: 123

Group type: COMPARATOR
Intervention: Brochure only (Control)
Number of subjects: 123
Study: 22799492

Group type: EXPERIMENTAL
Intervention: Read to Me! literacy package
Number of subjects: 1051

Group type: COMPARATOR
Intervention: Control (no literacy package)
Number of subjects: 1051
Study: 21050287

Group type: EXPERIMENTAL
Intervention: Lp-PLA₂ activity
Number of subjects: 19037

Group type: EXPERIMENTAL
Intervention: Lp-PLA₂ mass
Number of subjects: 19037

Group type: EXPERIMENTAL
Intervention: Apolipoprotein-B100
Number of subjects: 19037

Group type: COMPARATOR
Intervention: Simvastatin
Number of subjects: 19037
Study: 18156658

Group type: EXPERIMENTAL
Intervention: Carbohydrate supplementation (0.25 g.kg(‐1).h(‐1)) during hours 0-12 and 24-36 postexercise
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo (equal volume) during hours 0-12 and 24-36 postexercise
Number of subjects: 8
Study: 15955653

Group type: EXPERIMENTAL
Intervention: 80w/v% trichloroacetic acid (TCA)
Number of subjects: 169

Group type: COMPARATOR
Intervention: NonTCA treatment
Number of subjects: 169
Study: 12196838

Group type: EXPERIMENTAL
Intervention: Ganciclovir (GCV) + Intravenous Immunoglobulin (IVIG)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (prednisone, glucurone, Luminal, Xiaoyanlidanpian)
Number of subjects: 25
Study: 9934915

Group type: EXPERIMENTAL
Intervention: Instillation of intratracheal surfactant (80 mL/m2)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 42
Study: 8689457

Group type: EXPERIMENTAL
Intervention: hylan G-F 20 with NSAID continuation
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: hylan G-F 20 alone (NSAID discontinuation)
Number of subjects: 102

Group type: COMPARATOR
Intervention: NSAIDs alone
Number of subjects: 102
Study: 2178582

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (500 mg)
Number of subjects: 202

Group type: EXPERIMENTAL
Intervention: Sulfamethoxazole and trimethoprim (160 mg/800 mg)
Number of subjects: 202

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 202
Study: 375377

Group type: EXPERIMENTAL
Intervention: Cimetidine (0.6 mg.kg‐1h‐1)
Number of subjects: 4
Study: 30863045

Group type: EXPERIMENTAL
Intervention: tiotropium + olodaterol
Number of subjects: 15000
Study: 28633627

Group type: EXPERIMENTAL
Intervention: Motivational intervention (400 patients), delivered by a nurse trained by an expert psychologist, in 32 sessions (1 to 12 fortnightly, 13 to 32 monthly) on top of standard diet and exercise
Number of subjects: 864

Group type: COMPARATOR
Intervention: Control group (446 patients), received usual follow-up
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Motivational intervention
Number of subjects: 864
Study: 26712979

Group type: EXPERIMENTAL
Intervention: Tranexamic acid (TA) 20 mg/kg diluted to 25 cc with normal saline (Group T)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Normal saline (Group C)
Number of subjects: 80
Study: 25044176

Group type: EXPERIMENTAL
Intervention: Colecalciferol (280 μg daily for 2 weeks, then 140 μg daily for 10 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 22469604

Group type: EXPERIMENTAL
Intervention: Cyclamen europaeum nasal spray (CE) once daily for 15 days
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cyclamen europaeum nasal spray (CE)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Placebo nasal spray
Number of subjects: 99
Study: 19578802

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol + cyproterone acetate
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol + drospirenone
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: ethinyl estradiol + gestodene
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (not taking OC)
Number of subjects: 25
Study: 18075447

Group type: EXPERIMENTAL
Intervention: 30 mg of prednisone for 5 days preoperatively and 9 days postoperatively
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo for 5 days preoperatively and 9 days postoperatively
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Prednisone
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: POSE scoring system
Number of subjects: 26
Study: 15191588

Group type: EXPERIMENTAL
Intervention: Guided Tissue Regeneration (GTR) surgery
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Conventional Flap (CF) surgery
Number of subjects: 27

Group type: COMPARATOR
Intervention: Control sites (unaffected healthy sites)
Number of subjects: 27
Study: 12361815

Group type: EXPERIMENTAL
Intervention: Caspofungin (50 mg) intravenously once daily for 7 to 21 days
Number of subjects: 177

Group type: COMPARATOR
Intervention: Fluconazole (200 mg) intravenously once daily for 7 to 21 days
Number of subjects: 177

Group type: EXPERIMENTAL
Intervention: Caspofungin
Number of subjects: 177

Group type: COMPARATOR
Intervention: Fluconazole
Number of subjects: 177
Study: 9441569

Group type: EXPERIMENTAL
Intervention: Computer‐generated reminders
Number of subjects: 1009

Group type: COMPARATOR
Intervention: No reminders
Number of subjects: 1009

Group type: EXPERIMENTAL
Intervention: Both types of reminders
Number of subjects: 1009
Study: 10030329

Group type: EXPERIMENTAL
Intervention: Sulphadoxine-pyrimethamine
Number of subjects: 1264

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1264
Study: 2000036

Group type: EXPERIMENTAL
Intervention: Max EPA (fish oil concentrate)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Olive oil
Number of subjects: 27

Group type: COMPARATOR
Intervention: Olive oil with added cholesterol (same amount as in Max EPA)
Number of subjects: 27
Study: 6666227

Group type: EXPERIMENTAL
Intervention: 20 mg ISDN sustained-release, three times a day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 40 mg ISDN sustained-release, three times a day
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: 60 mg ISDN sustained-release, three times a day
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 28463015

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I), delivered in a six-session group program
Number of subjects: 81

Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy for Insomnia (CBT-I)
Number of subjects: 81
Study: 29273847

Group type: EXPERIMENTAL
Intervention: Apically positioned flap (APF)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APF plus xenogeneic collagen matrix (XCM)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APF plus free gingival graft (FGG)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: APF
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: XCM
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: FGG
Number of subjects: 0
Study: 27145292

Group type: EXPERIMENTAL
Intervention: tACSbm (20 Hz and < 400 μA for 30-min)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (usual rehabilitation program without tACSbm)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: tACSbm
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 60
Study: 24224808

Group type: EXPERIMENTAL
Intervention: Triple therapy with rabeprazole 10 mg b.i.d./q.i.d., amoxicillin 500 mg q.i.d, and sitafloxacin 100 mg b.i.d. (RAS) for 1 week
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Triple therapy with rabeprazole 10 mg b.i.d./q.i.d., amoxicillin 500 mg q.i.d, and sitafloxacin 100 mg b.i.d. (RAS) for 2 weeks
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Triple therapy with rabeprazole 10 mg b.i.d./q.i.d., metronidazole 250 mg b.i.d., and sitafloxacin 100 mg b.i.d. (RMS) for 1 week
Number of subjects: 180

Group type: EXPERIMENTAL
Intervention: Triple therapy with rabeprazole 10 mg b.i.d./q.i.d., metronidazole 250 mg b.i.d., and sitafloxacin 100 mg b.i.d. (RMS) for 2 weeks
Number of subjects: 180
Study: 22209180

Group type: EXPERIMENTAL
Intervention: Intramuscular (IM) injection of 8 mg dexamethasone
Number of subjects: 20

Group type: COMPARATOR
Intervention: Consumption of 8 mg dexamethasone
Number of subjects: 20
Study: 20353116

Group type: EXPERIMENTAL
Intervention: Guangming (GB 37)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hegu (LI 4)
Number of subjects: 0
Study: 18182457

Group type: EXPERIMENTAL
Intervention: pegylated-IFN-alpha2b
Number of subjects: 90

Group type: COMPARATOR
Intervention: antiretroviral therapy alone
Number of subjects: 90
Study: 16437191

Group type: EXPERIMENTAL
Intervention: Educational leaflet (Group A)
Number of subjects: 745

Group type: COMPARATOR
Intervention: Current practice (Group B)
Number of subjects: 745

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 745
Study: 14571490

Group type: EXPERIMENTAL
Intervention: aSIC-C stent
Number of subjects: 485

Group type: COMPARATOR
Intervention: Conventional stainless steel stent
Number of subjects: 485
Study: 10759077

Group type: EXPERIMENTAL
Intervention: Hearing sensitivity deterioration defined as an average deterioration of 10 dB/5 years at 3-4 kHz in at least one ear.
Number of subjects: 705

Group type: COMPARATOR
Intervention: Age group 41-50 years
Number of subjects: 705

Group type: COMPARATOR
Intervention: Gender (Males)
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Hearing sensitivity at 3-4 kHz
Number of subjects: 705

Group type: EXPERIMENTAL
Intervention: Hearing sensitivity at 0.5-2 kHz
Number of subjects: 705
Study: 9299805

Group type: COMPARATOR
Intervention: BIGCBT without medication
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: BIGCBT plus anti-anxiety medication
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: BIGCBT plus anti-depressant medication
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: BIGCBT plus combined anti-anxiety and anti-depressant medications
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: BIGCBT (with or without pharmacotherapy)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: BIGCBT with pre-existing pharmacotherapy
Number of subjects: 106
Study: 8436059

Group type: EXPERIMENTAL
Intervention: Citric acid aerosol inhaler used instead of a cigarette whenever the urge to smoke occurred during the first 12 days of the cessation period.
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Citric acid aerosol inhaler
Number of subjects: 74
Study: 3091405

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate (50 mg)
Number of subjects: 24
Study: 30223139

Group type: EXPERIMENTAL
Intervention: Mobile Cognitive Therapy for recurrent depression
Number of subjects: 264

Group type: EXPERIMENTAL
Intervention: Endorsement of habitual relative to functional responses on the DAS
Number of subjects: 264

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 264
Study: 29804406

Group type: EXPERIMENTAL
Intervention: Fiberoptic bronchoscope positioning laryngeal mask
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Ultrasound positioning laryngeal mask
Number of subjects: 120

Group type: COMPARATOR
Intervention: Traditional standard positioning laryngeal mask
Number of subjects: 120
Study: 26739717

Group type: EXPERIMENTAL
Intervention: KB003 (400 mg)
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: KB003 in eosinophilic asthmatics
Number of subjects: 160

Group type: COMPARATOR
Intervention: Placebo in eosinophilic asthmatics
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: KB003 in patients with FEV1 reversibility ≥ 20%
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: KB003 in patients with prebronchodilator FEV1 ≤ 50% predicted
Number of subjects: 160
Study: 24472704

Group type: EXPERIMENTAL
Intervention: Quercetin (single-dose and repeated intake)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Quercetin (repeated intake)
Number of subjects: 10
Study: 22718590

Group type: EXPERIMENTAL
Intervention: Immediate loading (IL) protocol with implants (tioLogic; Dentaurum, Ispringen, Germany)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (K1)
Number of subjects: 25
Study: 20718771

Group type: EXPERIMENTAL
Intervention: Testosterone undecanoate (TU; 1000 mg IM)
Number of subjects: 184

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 184
Study: 17620637

Group type: EXPERIMENTAL
Intervention: Azithromycin 500 mg/day for 5 days/month, repeated monthly for a maximum of 4 months
Number of subjects: 49

Group type: COMPARATOR
Intervention: Glucantime 60 mg/kg intramuscular for 20 days
Number of subjects: 49
Study: 15840739

Group type: EXPERIMENTAL
Intervention: Teriparatide (20 or 40 microg)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 61
Study: 11973184

Group type: EXPERIMENTAL
Intervention: Remifentanil (bolus 1 microg/kg; infusion 0.1‐0.2 microg x kg(‐1) x min(‐1))
Number of subjects: 81

Group type: COMPARATOR
Intervention: Fentanyl (2 microg/kg, and 1 microg/kg every 45 min)
Number of subjects: 81

Group type: EXPERIMENTAL
Intervention: Both Remifentanil and Fentanyl
Number of subjects: 81
Study: 8197844

Group type: EXPERIMENTAL
Intervention: Ibuprofen treatment for 10 days postoperatively
Number of subjects: 57

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 57
Study: 3581699

Group type: EXPERIMENTAL
Intervention: Saline washout
Number of subjects: 20

Group type: COMPARATOR
Intervention: Control group (intra-articular saline injection)
Number of subjects: 20